Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: Plasma asymmetric dimethylarginine levels decrease with age

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 11, 2007, Pages 1525-1530

  Lücke, Thomas ^a,c   Kanzelmeyer, Nele ^a   Kemper, Markus J ^b   Tsikas, Dimitrios ^a   Das, Anibh M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NONE   (Germany)

Author keywords

Age dependency; Asymmetric dimethylarginine (ADMA); Childhood; Infancy; Nitric oxide (NO); Nitric oxide synthase (NOS)

Indexed keywords

ARGININE; DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE;

ADOLESCENT; ADULT; ADULTHOOD; AGE DISTRIBUTION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHILD; CORRELATION COEFFICIENT; DEVELOPMENTAL STAGE; GAS CHROMATOGRAPHY; HUMAN; INFANCY; INFANT; MASS SPECTROMETRY; NEWBORN; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

ADOLESCENT; ADULT; AGE FACTORS; ARGININE; CHILD; CHILD, PRESCHOOL; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFANT; INFANT, NEWBORN; MALE; NITRIC OXIDE;

EID: 35648988113     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.300     Document Type: Article

References (39)

1. Forstermann U. Endothelial NO synthase as a source of NO and superoxide. Eur J Clin Pharmacol 2006;62:(Suppl 13):5-12.
2. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-4.
3. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006;97:1676-89.
4. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006;147(Suppl 1):S193-201.
5. Rees D, Palmer R, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-8.
6. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489-509.
7. Tolins JP, Palmer RM, Moncada S, Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990;258:H655-62.
8. Tsikas D, Gutzki FM, Stichtenoth DO. Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: methods of analysis. Eur J Clin Pharmacol 2006;62(Suppl 13):51-9.
9. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20(Suppl 12):S60-2.
10. Tsikas D, Boger RH, Sandmann J, Bode-Boger SM, Frolich JC. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 2000;478:1-3.
11. Leiper JM, Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006;62(Suppl 13):33-8.
12. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG,NG- dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo) 1995;117:237-8.
13. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-9.
14. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
15. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-52.
16. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
17. Al Banchaabouchi M, Marescau B, Possemiers I, D'Hooge R, Levillain O, De Deyn PP. NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal insufficiency. Pflugers Arch 2000;439:524-31.
18. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
19. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9.
20. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:489-92.
21. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993;11:1375-80.
22. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006;40:295-302.
23. Maas R, Boger RH. Old and new cardiovascular risk factors: from unresolved issues to new opportunities. Atheroscler Suppl 2003;4:5-17.
24. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006;62(Suppl 13):39-44.
25. Boger RH, Bode-Boger SM, Brandes RP, Phivthongngam L, Bohme M, Nafe R, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997;96:1282-90.
26. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
27. Tsikas D, Schubert B, Gutzki FM, Sandmann J, Frolich JC. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J Chromatogr B 2003;798:87-99.
28. Tsikas D. Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem 2000;72:4064-72.
29. Tsikas D, Wolf A, Frolich JC. Simplified HPLC method for urinary and circulating creatinine. Clin Chem 2004;50:201-3.
30. Elli M, Soylemezoglu O, Erbas D, Bakkaloglu SA, Buyan N, Ozkaya O, et al. Plasma and urine nitric oxide levels in healthy Turkish children. Pediatr Nephrol 2005;20:1605-9.
31. Liappis N, Gobien N, Schlebusch H. [Reference values of fasting serum levels of free amino acids in children]. Klin Padiatr 1990;202:161-7. In German.
32. Lücke T, Tsikas D, Kanzelmeyer NK, Vaske B, Das AM. Elevated plasma concentrations of endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia. Metabolism 2006;55:1599-603.
33. Lücke T, Tsikas D, Kanzelmeyer NK, Boerkoel CF, Clewing JM, Vaske B, et al. Vaso-occlusion in Schimke-immuno-osseous dysplasia: is the NO pathway involved? Horm Metab Res 2006;38:678-82.
34. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111-6.
35. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B 2006;851:42-50.
36. Martens-Lobenhoffer J, Bode-Boger SM. Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids. J Chromatogr B 2006;851;30-41.
37. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B 2006;851:21-29.
38. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005;46:1693-701.
39. Surdacki A, Tsikas D, Mayatepek E, Frolich JC. Elevated urinary excretion of nitric oxide metabolites in young infants with Zellweger syndrome. Clin Chim Acta 2003;334:111-5.